1. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma;Ansell;N. Engl. J. Med.,2014
2. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013);Craig,2014
3. Efficacy and Safety of Nivolumab vs Investigator's Choice Chemotherapy (ICC) in Subgroups of Patients with Advanced Melanoma after Prior Anti-CTLA-4 Therapy;D'Angelo,2014
4. Antitumor activity of pembrolizumab (Pembro; MK-3475) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients (pts) with advanced non-small cell lung carcinoma (NSCLC);Garon,2014
5. KEYNOTE 012: triple negative breast cancer;Nanda,2014